New eczema cream shows promise for infants in safety trial
NCT ID NCT06998056
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a cream called roflumilast (0.05%) applied once daily for 4 weeks in 101 infants aged 3 months to 2 years with mild-to-moderate eczema. The main goal was to see if the cream is safe and well-tolerated. Researchers tracked side effects, serious side effects, and skin reactions at the application site.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
roflumilast cream 0.05%
What this could lead to
If successful, this could provide a new topical treatment option for infant eczema that is safe and easy to use.
What could go wrong
This is an early-phase safety study with only 101 infants and no placebo comparison. It does not measure how well the cream works, only its safety. Side effects may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (ECZEMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arcutis Clinical Study Site 201
Santo Domingo, 10306, Dominican Republic
-
Arcutis Clinical Study Site 202
San Antonio, Texas, 78218, United States
-
Arcutis Clinical Study Site 203
Winnipeg, Manitoba, R3J0S9, Canada
-
Arcutis Clinical Study Site 204
Halifax, Nova Scotia, B3K 5R3, Canada
-
Arcutis Clinical Study Site 206
Portland, Oregon, 97239, United States
-
Arcutis Clinical Study Site 207
Coral Gables, Florida, 33146, United States
-
Arcutis Clinical Study Site 208
Birmingham, Alabama, 35244, United States
-
Arcutis Clinical Study Site 209
Rancho Santa Margarita, California, 92688, United States
-
Arcutis Clinical Study Site 210
Bellaire, Texas, 77401, United States
-
Arcutis Clinical Study Site 211
Portsmouth, New Hampshire, 03801, United States
-
Arcutis Clinical Study Site 212
Minneapolis, Minnesota, 55112, United States
-
Arcutis Clinical Study Site 213
Jacksonville, Florida, 32256, United States
-
Arcutis Clinical Study Site 214
Fountain Valley, California, 92708, United States
-
Arcutis Clinical Study Site 216
Waterloo, Ontario, N2J1C4, Canada
-
Arcutis Clinical Study Site 217
Delray Beach, Florida, 33484, United States
-
Arcutis Clinical Study Site 219
West Lafayette, Indiana, 47906, United States
-
Arcutis Clinical Study Site 220
Mason, Ohio, 45040, United States
-
Arcutis Clinical Study Site 221
Bryant, Arkansas, 72022, United States
-
Arcutis Clinical Study Site 222
Summerville, South Carolina, 29486, United States
-
Arcutis Clinical Study Site 223
Boise, Idaho, 83706, United States
-
Arcutis Clinical Study Site 224
Fort Worth, Texas, 76244, United States
-
Arcutis Clinical Study Site 225
Saskatoon, Saskatchewan, S7K2C1, Canada